Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT in MDD With and Without IBS
NCT05174273Phase 3Active, not recruiting
- Start
- Apr 2022
- Primary completion
- Oct 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 3 trial of allogeneic fecal microbiota in major depressive disorder (MDD), irritable bowel syndrome (IBS). Started Apr 2022; status: active, not recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
major depressive disorder (MDD)irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT05174273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05174273.